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Understanding the dose–concentration–effect relationship is a fundamental component of clinical pharmacology. Interpreting
data arising from observations of this relationship requires the use of mathematical models; i.e. pharmacokinetic (PK) models to
describe the relationship between dose and concentration and pharmacodynamic (PD) models describing the relationship
between concentration and effect. Drug development requires several iterations of pharmacometric model-informed learning
and conﬁrming. This includes modelling to understand the dose–response in preclinical studies, deriving a safe dose for ﬁrst-
in-man, and the overall analysis of Phase I/II data to optimise the dose for safety and efﬁcacy in Phase III pivotal trials. However,
drug development is not the boundary at which PKPD understanding and application stops. PKPD concepts will be useful to
anyone involved in the prescribing and administration of medicines for purposes such as determining off-label dosing in special
populations, individualising dosing based on a measured biomarker (personalised medicine) and in determining whether lack of
efﬁcacy or unexpected toxicity maybe solved by adjusting the dose rather than the drug. In clinical investigator-led study design,
PKPD can be used to ensure the optimal dose is used, and crucially to deﬁne the expected effect size, thereby ensuring power
calculations are based on sound prior information. In the clinical setting the most likely people to hold sufﬁcient expertise to
advise on PKPDmatters will be the pharmacists and clinical pharmacologists. This paper reviews fundamental PKPD principles and
provides some real-world examples of PKPD use in clinical practice and applied clinical research.
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Introduction
When a medicine is prescribed, the purpose is to derive an
effect that usually evolves with time. Whilst the deﬁnition
of a medicine now encompasses small molecules, biologics
and gene therapy, there remains a fundamental requirement
to understand the dose–response relationship in order to
determine how much and how frequently to administer a
treatment. Paracelsus, widely regarded as the founder of mod-
ern toxicology, wrote: “Poison is in everything… the dosage
makes it either a poison or a remedy”. This should be consid-
ered regardless of the treatment in question: for example,
marathon runners often poison themselves by drinking too
much water [1]. It is important to consider dosing in both
clinical practice and research, which requires an understand-
ing of pharmacokinetics (PK) and pharmacodynamics (PD).
In this paper the term modelling refers to mathematical
and statistical modelling. The mathematical model is deﬁned
as an equation used to relate known covariates (dose given,
time of dose, time of observations) with observed measure-
ments. In the case of the PK 1 compartment intravenous
bolus model, the concentration measured at time t is given
by: ĉ(t) = D/Ve–CL/Vt, where D is the known dose, V and CL
are the model parameters volume of distribution and clear-
ance, and ĉ(t) is the model prediction of concentration at
some time t. Using this assumed mathematical model, the
values of the parameters V and CL are sought that minimise
the difference between the model prediction and observed
concentrations; this is the statistical model, which in the sim-
plest case of single subject data, is given by: c(t) = ĉ(t) + ε,
where c(t) is an observed concentration at time t, and ε
denotes the deviation of themodel prediction from the obser-
vation. Statistical modelling seeks to minimise the value of ε
by searching for the optimal values of the model parameters
(V and CL). All models are gross simpliﬁcations of the system
under study, and so the goal of PKPD modelling is often to
test a range of models to determine which ﬁts best. Clinical
pharmacologists tend to choose speciﬁc models using a
knowledge of the system that generated the observed data;
this will be discussed in more detail below.
In clinical practice and research, the study of PK only is
usually conﬁned to a limited set of circumstances where the
PD can be readily inferred from a measured concentration.
An example of this is antimicrobial chemotherapy, where
the relationship between the minimal inhibitory concentra-
tion (determined in vitro) is linked with maximum concentra-
tion (Cmax), area under the (concentration–time) curve (AUC)
or fraction of a dose interval is spent with concentrations
above the minimal inhibitory concentration [2]. In many sit-
uations one wishes to also model the PD in order to under-
stand the full dose–concentration–effect relationship, or
occasionally one may not have easy access to PK measures
and seek to model the dose–response, otherwise known as
K-PD models. PD can encompass a wide variety of measure-
ment types, all of which can be described in mathematical
terms with parameter values estimated using statistical
modelling. In recent years, the term pharmacometrics has
gained popularity. Pharmacometrics encompasses the
analysis of PK and PD data, and then uses resulting models
to make inferences (often using simulation) on optimum
dosing for clinical trials or practice.
An understanding of pharmacometric modelling and
simulation, and how it can give insights into the
dose–concentration–effect relationship, will be useful to all
clinical pharmacists and pharmacologists. This article seeks
to set out the basic principles, ﬁrstly through providing
detailed answers to a series of common questions, followed
by a section giving some brief examples on some real-world
applications of pharmacometric modelling in clinical
practice and research.
Why are (mechanism-based)
mathematical and statistical models
required to understand
pharmacometric data?
Biological systems are inherently nonlinear, and deﬁning a
target exposure or concentration through simple observa-
tions of raw data can be difﬁcult. For example, in Figure 1, a
plot of the PK model-predicted remifentanil concentrations
vs. observed mean arterial blood pressure (MAP) measure-
ments have been made using data collected on a study in in-
fants prior to craniofacial surgery [3]. The anaesthetists in
this study used remifentanil to control MAP in order to re-
duce bleeding in the operative ﬁeld. The aim of this study
was to therefore combine measurement of remifentanil PK
with measures of MAP (PD) to estimate the parameters of a
PKPD model that would be used to deﬁne a target concentra-
tion (along with appropriate dose to reach that concentra-
tion) to yield a 30% drop in MAP. Through simple
observation of these data, deﬁning an appropriate target
concentration is challenging for two main reasons:
Firstly, hysteresis is clearly present in that the same effect
(MAP) can be seen at different observed concentrations
within a patient. This comes about due to the fact that circu-
lating concentrations are in ﬂux coupled to the delay in the
drug reaching the site of action, binding to its target and
eliciting its effect. Nonlinearmathematical PK and PDmodels
coupled with an effect compartment model were used to
Figure 1
Model predicted remifenatanil concentration vs. mean arterial
pressure (MAP) in infants prior to craniofacial surgery [3]. Different
symbols and colours represent data points from each patient
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describe this phenomenon, deﬁne the target effect site
concentration, and then to suggest a dose yielding this con-
centration in a typical patient. Here the word nonlinear refers
to the fact that the PK (a two-compartment model) and the
PD (sigmoidal Emax model) were not expressed as linear
y = mx + c type models. The term effect compartment refers to
an additional compartment with ﬁrst order equilibration rate
constant between it and the central compartment, which was
used in the PD model to account for hysteresis.
The concept of a typical patient, or average expected
response in the population of interest, brings us to the second
challenge for interpreting these data: namely that there is a
clear interindividual variability between patients. Ignoring
the correlation between each individual’s data points when
ﬁtting the PKPDmodel (the so-called naïve pooled approach)
may bias parameter estimates and will inﬂate the amount of
unexplained variability in the model. For this reason, mixed
effects analysis, or the so-called population approach, must be
used for parameter estimation during statistical model ﬁtting
[4–8]. For a full account of the model-building process in this
example, readers are referred to the original article, which
contains an appendix of the model code [3].
What biological prior information do
pharmacometric modellers use to
inform model choices?
Beware the mathematician or statistician who, upon seeing
PK or PD data, questions the proposed pharmacological
model and suggests an empirical alternative. At its extreme,
statisticians are now suggesting multimodel approaches
whereby several models are simultaneously ﬁtted, the weight
given to each model adjusted according to how well it ﬁts the
data [9]. Whilst such approaches are undoubtedly useful for
ﬁtting and describing observed data, large sample sizes and
exposure ranges will be required to characterise the popula-
tion response and extrapolation outside the studied popula-
tion will not be straight-forward without biologically
interpretable parameters. By ignoring the extensive biologi-
cal prior information that we, as pharmacologists, have on
the system that generated the data, empirical modelling ap-
proaches are rarely useful for application in clinical settings
where small datasets are available, and the goal is often to
extrapolate ﬁndings in one population to another, to use
ﬁndings of one study to plan another (the learning and
conﬁrming paradigm [10]), or to apply ﬁndings to dose
adjustment in direct patient care.
In the case of a physiologically-based PK (PBPK) model,
with tissue volumes, blood ﬂows and partition coefﬁcients
added to the model a priori rather than ﬁtted to observed PK
data, it is clear from where the biological priors come. How-
ever, even the simple 1-compartment PK model [11]
parametrised with clearance (CL) and volume (V) carries
biological interpretation.
The fact that CL is a parameter with units of volume per
time, whichmatch blood ﬂows and glomerular ﬁltration rates
(GFRs) for example, and is related to the AUC through
CL = dose/AUC allows one to leverage prior information.
For example, the CL of tobramycin, which is eliminated
primarily by glomerular ﬁltration, in a typical 70 kg individ-
ual is around 140 ml min1 [12], or slightly higher than a
normal GFR. Say tobramycin was a new drug, and from its
physicochemical properties (large polar molecule) and
preclinical data (excreted unchanged in the urine) one knew
it was likely to be excreted by glomerular ﬁltration, ﬁrst-
in-man dosing could be rationally planned to attain target
concentrations (recall that average concentration is given
by AUC(0-t)/t) in the desired nontoxic ranges, and it would
come as no surprise to the pharmacologist to ﬁnd CL to be
similar to GFR in these studies. This biological prior
knowledge would then allow dosing to be planned to attain
target concentrations in subsequent studies in populations
with different GFRs (e.g. elderly, hyperﬁltrating ICU patients,
children).
In the case of V, the apparent volume of distribution,
whilst it does not represent the volume of an actual physio-
logical compartment, biological prior information can still
be utilised. For example, diclofenac is highly bound to plasma
proteins, so it should come as no surprise that its estimated
central V for a typical 70 kg individual is around 3.68 l [8],
which is similar to normal plasma volume [13]. For a highly
protein bound drug such as diclofenac, one would expect V
to have a linear relationship with body weight since blood
volume is proportional to weight [13]. For drugs with larger
distribution volumes, particularly where partition to body
fat maybe important in obese patients, models for predicting
lean body weight or fat-free mass are now available for adults
[14, 15] and children [16]. Using biological prior information
such as this can help to predict maximal concentrations and
elimination half-lives in populations of interest.
With regard to PD models, there are two main consider-
ations. The ﬁrst is on the observed response, its time course
and its type (usually a measured biomarker or clinical out-
come such as disease score). The observed response will be
heterogeneous and disease speciﬁc and whether biological
prior information can be used to inform modelling is vari-
able. For example, drug-induced neutropaenia has been suc-
cessfully described using a mechanistic model of the
simpliﬁed life-span of a neutrophil, with most cytotoxic
chemotherapy agents acting on the proliferating precursor
cells [17]. On the other hand, sometimes PD endpoints are
measured by a score (for example the Paediatric Crohn’s
Disease Activity Index [18]) whereby the introduction of
biological prior information on probabilistic PD models is
less straightforward. The second consideration with PD
models is the concentration–response effect at the site of drug
action, which is then often used to drive the observed PD
time course, often through an effect compartment, or using
indirect response models [19]. Here, the well-established Hill
(or Emax) model is used, which can be derived from the law of
mass action (see derivation in [20]), and provides a mechanis-
tic basis for the concentration–effect relationship.
How do pharmacometric models scale
with size and age?
In paediatrics, it is well established that smaller children
need smaller doses, but this is often lost in the one-dose-
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ﬁts all world of adult medicine. Adult clinical studies in
high-proﬁle journals often do not recognise that body size
is an important determinant of drug exposure and conse-
quently ought to be corrected for. This is particularly im-
portant for drugs requiring optimised exposure for effect
(e.g. anti-infective agents) or those with a narrow therapeu-
tic index. For example, Nijland et al [21] state that rifampi-
cin exposure is strongly reduced in patients with type II
diabetes whereas the majority of the difference in exposure
between nondiabetics and Type II diabetics is explained by
the Type II diabetics being heavier. Takahashi et al [22]
meanwhile emphasised genetic differences as the major
causative factor behind an observation that a cohort of
African–American, Caucasian and Japanese patients needed
different doses of warfarin. Body weights in these cohorts
were not matched, and the African–American patients were
heavier than the Caucasian patients, who in turn were
heavier than the Japanese patients. Dividing the dose by
the weight shows all ethnic groups in this study were on
0.06 mg kg1, and from the reported regression coefﬁcients
being heterozygous for any CYP2C9 polymorphism or
VKORC1 1173 C > T has the same effect as a 55 kg or
42 kg difference in body weight, respectively. This poses
the question as to why a ﬂat 10 mg induction regimen is
recommended in all adults whether they weigh 40 kg or
120 kg, whereas prescribers are warned about potential ge-
notypic effects in the summary of product characteristics.
Accepting that PK scales with size, it is then important to
consider how important PK parameters scale. In 1947, in his
treatise on scaling of basal metabolic rate with size and it
implications, Kleiber [23] stated:
“For the dosage of drugs one should know whether or not
the action depends on reaching a certain concentration in
the blood stream without regard to its further
maintenance. In this case the dosage should be propor-
tional to body weight, since the amount of blood is pro-
portional to body weight. If, however, the action of the
biotic depends on the maintenance of a given concentra-
tion over a period of time, and if the rate of destruction or
excretion of the biotic is proportional to the metabolic
rate, then the dosage should be based on the metabolic
body size.”
In other words, volumes scale with linear body weight,
and hence drugs for which a threshold concentration is
required (e.g. aminoglycoside Cmax targets) should be dosed
by body weight, whereas, in the case of most drugs, where
PD is driven by exposure (recall AUC = dose/CL) metabolic
weight, meaning weight raised to a power of 3/4, should be
used. This metabolic weight is quite similar to body surface
area (weight raised to a power of 2/3) and paediatricians have
long since known to dose narrow therapeutic index drugs by
surface area [24]. Scaling of clearance by metabolic weight
does not only apply to small molecules, but also biologics
[25]. Here it must be noted that these principles apply to
drugs with both linear and nonlinear pharmacokinetics, but
with Michaelis–Menten elimination it is Vm that should
scale allometrically, with Km constant across size and ages.
Returning to the linear PK case, this difference in the
way that CL and V scale with size means that smaller peo-
ple have shorter half-lives due to their proportionally
higher CL and therefore elimination rate constant.
Figure 2 gives an illustration of how CL, V and half-life
are expected to vary with size and age according to the
principles described above. Unfortunately, this subtlety
was lost in a British Medical Journal study ﬁnding shorter
caffeine half-lives (the paper incorrectly asserts half-life to
be a proxy for CL) in pregnant women were associated
with lower birth weights (P = 0.06), caffeine with its
Figure 2
Illustration of the relative expected changes in clearance (CL) volume of distribution (V) and elimination half-life with weight (based on allometric
principles) and age for the one-compartment intravenous bolus model. The standard value for weight here is set to 70 kg, so CL and V take the
value 1
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metabolites being somehow responsible for fetal growth re-
striction [26]. There are three fundamental problems with
the analysis of these data that would be spotted by a com-
petent PK expert. Firstly, one cannot estimate half-life from
oral PK data without also estimating an absorption rate
constant (which might reasonably be ﬁxed to a sensible
value if no data in the absorption phase were gathered),
V (to transform the dose input into a concentration) and
CL (from which and V, the elimination rate constant can
be derived along with half-life should one wish). The au-
thors do not mention V or absorption rate constant, so im-
mediately the reader will be concerned about how exactly
half-life was estimated. The second problem is that empiri-
cal linear covariate analysis was done on half-life, includ-
ing correlated items such as age and weight, without prior
consideration of the biological system that derived the
data. Caffeine is largely eliminated by CYP1A2-mediated
hepatic metabolism [27] so one would expect larger indi-
viduals with larger livers to have a greater capacity for
caffeine metabolism. Given the weight range reported, the
caffeine half-life for the smallest woman would be approx-
imately 20% shorter than that of the largest woman based
on allometric principles, and this relationship would be
nonlinear. Given that we therefore expect smaller women
to have shorter half-lives, and given that birth weight
and maternal weight are correlated so we expect smaller
women to have smaller babies, ideally one would correct
for size a priori to delineate this effect from other covariates
of interest. Finally, half-life is a continuous variable yet the
authors arbitrarily dichotomised the group into fast and
slow ﬁnding a weak (P = 0.06) association between fast
half-life and low birth weight. It would have been interest-
ing to see whether this relationship would have held had
CL been estimated and the test conducted on this continu-
ous variable.
Size scaling, when done properly as described above,
tends to work well in children older than 2 years but, in youn-
ger patients, maturation of drugmetabolising enzyme expres-
sion and glomerular ﬁltration means that age needs to be
taken into account. Various methods for size and age scaling
are available, the most sensible of which was recently set out
and proposed as a standard scaling method [28]. Whilst size
and age scaling are now well established for PK models, and
it has been proposed in many cases that with proper PK
scaling PD can be predicted in children [29], there are some
PD endpoints (e.g. drug effects on the developing adaptive
immune system [30]) where size and age may need to be
considered in PD modelling.
What is meant by population PKPD?
The population approach when applied in pharmacometrics
is used to refer to the statistical aspect of model ﬁtting called
mixed effects or multilevel modelling. By ﬁtting models, the
goal is to estimate the most likely values of parameters (e.g.
CL and V) from a set of observed data (e.g. concentrations)
along with known covariates (e.g. dose, time, body weight).
Whilst the standard goal of model ﬁtting by regression is to
minimise a residual departure of model predictions from
observed data points, since PKPD data include multiple data
points from several individuals, it is necessary to account
for the correlations of data points within individuals so as
not to bias parameter estimates and inﬂate unexplained vari-
ability. For this reason, in addition to a data point level of var-
iability, mixed effects modelling has a parameter level of
variability, allowing parameters to vary between individuals.
Population analysis can be used for rich or sparse data. The
rule-of-thumb deﬁnition for rich data is at least as many sam-
ples per subject as model parameters [31], with fewer samples
per subject than model parameters being called sparse data.
This deﬁnition may, however, be too simplistic because the
timing of samples can bemore important than the total num-
ber. For example, multiple samples towards the end of an oral
administration PK curve will give little information on vol-
ume and absorption parameters. It is now possible to use op-
timal design, a technique using a previous or assumedmodel,
to deﬁne optimally informative sampling times so that data
collected will give precise estimates of model parameters
[32]. The end result of a population pharmacometric model
ﬁtting exercise is a set of typical population model parame-
ters, their variance, and the variance of the residual
unexplained variability. This can then be used to generate
new hypotheses (e.g. what will be the expected
concentrations under different dosing conditions) or as a
Bayesian prior for personalised medicine. There are several
excellent reviews explaining the population approach to
PKPD analysis [5, 7, 33].
Some examples of pharmacometric
models used in the clinic
Dosing in special populations
Prescribing medicines outside the terms of their product
license (off-label) is common in hospital-based settings, par-
ticularly in paediatrics. Often when this is the case it may be
appropriate to adjust dosing and here the clinical pharmacist
or pharmacologist with a sound understanding of PKPD prin-
ciples will be able to help. An example of this arose in around
2009 when the infectious diseases team at Great Ormond
Street Hospital wanted to use posaconazole, which was unli-
censed in children. At the time, there were published PK data
on only two children (aged 8 and 10 years) [34] so to predict
dosing in younger patients required extrapolation. It was
known that posaconazole is hepatically metabolised (so CL
should follow allometric 3/4 scaling) and that the major met-
abolic pathway was glucuronidation. The maturation of
glucuronidation was known through studies on paracetamol
andmorphine [35]. Assuming that the target exposure should
be achieved by a dose achieving a similar AUC to the licensed
adult dose (200 or 400 mg), simply multiplying this dose by a
scaled typical weight for age and additionally the published
maturation function [35] (which takes values between 0 and
1, increasing with age) gave the following target doses to give
a similar exposure to 200 mg in adults: neonates 1.5 mg kg1;
infants aged 1 month-1 year 3 mg kg1; infants and children
aged 1 year or over 4 mg kg1 (maximum 200 mg). These
doses were then put forward to be used in the hospital pre-
scribing guidelines.
Pharmacometrics in clinical practice and research
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Personalised medicine
The term personalised medicine, which in recent years has
been hijacked by reductionist (pharmaco-)geneticists, can
have two meanings. Firstly, there is stratiﬁed medicine,
whereby treatment is personalised before a dose is given.
Sometimes this might be a genetic or other
clinical/biomarker that determines treatment choice, some-
times this might be a clinical/biomarker that determines
treatment dose. Paediatricians practice this second type of
stratiﬁed medicine every time a drug is prescribed, the dosing
being based on weight, age or surface area. Population PKPD
models can be used to identify important covariates that de-
termine response, and this may include genetic or
metabolomic markers alongside other factors, ideally in-
formed by biological prior information.
The second interpretation of personalised medicine arises
where a treatment is adjusted according to response (this may
also be called individualised medicine). Typically, this is done
with therapeutic drug monitoring, where the biomarker is
drug concentration, although the biomarker can just as easily
be a PD endpoint (e.g. International Normalized Ratio in re-
sponse to warfarin). In this context, rather than empirically
adjusting the dose until a target is reached, there is increasing
interest in using population PKPD models as Bayesian priors,
with the observed patient biomarker and covariate informa-
tion being used to construct a posterior set of most likely indi-
vidual model parameters to be used to predict/adjust future
treatment. A wide range of software applications are now
available for this [36], and applications beyond traditional
therapeutic drug monitoring [37] such as prediction of drug-
induced neutropaenia [38] and International Normalized Ra-
tio under warfarin therapy [39].
Managing overdose
PK principles are crucial in some overdose situations, most
notably with paracetamol where a PK-derived nomogram is
available to guide acetylcysteine therapy based on measured
paracetamol concentration. The PKPD-literate clinical phar-
macist or pharmacologist does not, however, need to limit ad-
vice giving solely to agents that have readily available
nomograms. One example was a query received regarding
persistent hypotension in a child following an accidental in-
travenous clonidine overdose. Using a published PKPD
model linking clonidine and mean arterial pressure (MAP)
[40], the trajectory of the expected hypotensive time course
given the dose received was easily plotted to show that resolu-
tion of the effect would be expected to take several more
hours.
Examples of pharmacometric models in
clinical pharmacology research
Developing dosing guidelines for a clinical trial
Pivotal clinical trials are often costly and time consuming so
getting the dose right, particularly for narrow therapeutic in-
dex agents, is of critical importance. Whilst many pharma-
ceutical companies integrate PKPD information throughout
early-phase development to get the dose right for Phase III,
it is also important that investigator-led clinical studies are
supported by clinical pharmacist or pharmacologist col-
leagues in study design. An example of this was during the de-
sign of a study to use insulin-like growth factor (IGF-1) in
children with Crohn’s disease [18]. It was proposed that
IGF-1 supplementation could be used to promote growth in
adolescents with Crohn’s disease and IGF-1 deﬁciency, but
since high IGF-1 levels may be carcinogenic, it was important
to ensure that the dosing would only correct levels up to the
normal range and not too far beyond. A small PK study was
performed in the target population, and covariate analysis
showed that in addition to the biological priors of size and
age (normal IGF-1 levels increase during adolescent growth),
disease severity measured by the PCDAI was required to tailor
dosing to endogenous IGF-1 production.
Defining the effect size for a clinical trial
The number of patients recruited to a clinical trial is governed
by the expected effect size of the tested treatment. In many
cases, investigators make over-optimistic predictions on the
expected effect size leading to trail failure due to inadequate
sample size [41]. This is an area where PKPD model predicted
outcomes are underutilised. In the planning of a randomised
double blind noninferiority trial of clonidine vs. midazolam
for sedation in neonatal and paediatric intensive care, the cli-
nician’s estimate of successful sedation with midazolam (the
control arm) was 85%, which led to a sample size of 90 (45 pa-
tients per group). The midazolam effect size was also evalu-
ated through simulation of expected concentrations using
the planned dose scheme, a published PK model [42, 43]
and a target PD concentration [44]. This gave an expected se-
dation success rate of 75%, which meant the necessary sam-
ple size increased more than three-fold to 300 patients (150
per group), and indeed this more conservative effect size will
be used in the proposed study.
Pharmacometric model parameters as trial
endpoints
In the drive to make clinical trials more efﬁcient, an interest-
ing idea has recently been proposed whereby the drug effect
parameter in a PKPD model could be used as a trial endpoint.
Often trial endpoints are tested as being a biomarker or clini-
cal observation at a speciﬁc, somewhat arbitrary time,
whereas if a drug effect parameter were used, data from the
whole response time course within a patient could be used.
Using the example of a viral kinetic model in hepatitis C in-
fection, Laouenan et al. [45] showed that the power to detect
a difference in drug effect between two competing therapies
could in some circumstances increase study power by 10-fold
as compared with using the single time-point outcome of
change in viral load at Day 14 of treatment. For diseases
where there are sufﬁcient data to build a prior population
PKPD model, this approach could be a paradigm for small
investigator-led clinical trial design.
Conclusion
In this paper, arguments for ensuring that pharmacometric
knowledge remains a central pillar of clinical pharmacology
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have been given. The implications of scaling PKPD responses
(in particular for size) and of interindividual variability in re-
sponses meaning individualisation of dosing or treatment
choice maybe required, are not always appreciated by the
wider clinical research community. Clinical pharmacists and
pharmacologists with this knowledge are ideally placed to in-
ﬂuence clinical management using pharmacometric princi-
ples. In addition, clinical trial design is increasingly being
seen as a specialist statistical subject. Clinical trials methodol-
ogists may not fully appreciate the value of the biological
prior information won over decades of clinical pharmacology
research; there seems a clear need for clinical pharmacists and
pharmacologists to become more involved in clinical trial
design.
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